Document is current
Any future updates will be listed below
-
Authors
Barba-Reyes, Juan M.
Harder, Lisbeth
Marco Salas, Sergio
Jaisa-aad, Methasit
Muñoz-Castro, Clara
Garma, Leonardo D.
Rafati, Nima
Nilsson, Mats
Hyman, Bradley T.
Serrano-Pozo, Alberto
Muñoz-Manchado, Ana B.
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (PID2022-136526OB-I00, PID2019-109046GA-I00)
European Regional Development Fund (PID2022-136526OB-I00, PID2019-109046GA-I00)
Prince Mahidol Award Youth Program
Martin L. and Sylvia Seevak-Hoffman Fellowship for Alzheimer’s Research
Real Colegio Complutense
US National Institute on Aging (P30AG062421, P30AG062421)
RyC programme (RYC-2017-22594)
Swedish Foundation for Strategic Research (FFL 18-0314)
Swedish Research Council (2017-03349)
Universidad de Cadiz
- License Information
-
More Information
Article History
Received: 13 February 2025
Revised: 15 April 2025
Accepted: 23 April 2025
First Online: 5 May 2025
Declarations
:
: Dr. Hyman owns stock in Novartis; he serves on the SAB of Dewpoint and has an option for stock. He serves on a scientific advisory board or is a consultant for AbbVie,Alexion, Ambagon, Aprinoia Therapeutics, Arvinas, Avrobio, AstraZenica, Biogen, Bioinsights, BMS, Cure Alz Fund, Cell Signaling, Dewpoint, Latus, Merck, Novartis, Pfizer, Sanofi, Sofinnova, Takeda, TD Cowen, Vigil, Violet, Voyager, WaveBreak. His laboratory is supported by research grants from the National Institutes of Health, Cure Alzheimer’s Fund, Tau Consortium, and the JPB Foundation—and a sponsored research agreement from Abbvie and Sanofi. He has a collaborative project with Biogen. Dr. Marco Salas is co-founder of spatialist AB, a spatial omics consulting company.
: The study does not include living human subjects. Samples were collected from autopsies and have been de-identified. Donors or their next-of-kin provided written informed consent for brain autopsy, and the study was approved by the review board of each brain bank.
